KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Interest & Investment Income (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Interest & Investment Income readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 19.05% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 million, a 27.65% decrease, with the full-year FY2025 number at $10.7 million, down 27.65% from a year prior.
  • Interest & Investment Income hit $2.9 million in Q4 2025 for Biocryst Pharmaceuticals, up from $2.2 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.5 million in Q4 2023 to a low of $9000.0 in Q3 2021.
  • Median Interest & Investment Income over the past 5 years was $2.8 million (2022), compared with a mean of $2.3 million.
  • Biggest five-year swings in Interest & Investment Income: tumbled 99.6% in 2021 and later soared 19455.56% in 2022.
  • Biocryst Pharmaceuticals' Interest & Investment Income stood at $14000.0 in 2021, then surged by 19214.29% to $2.7 million in 2022, then skyrocketed by 65.13% to $4.5 million in 2023, then decreased by 20.04% to $3.6 million in 2024, then decreased by 19.05% to $2.9 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.9 million (Q4 2025), $2.2 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.